18 January 2018
By Helen Kimberley and Julia Fraser
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has published an update to pharmaceutical companies in the UK on the status of the Brexit negotiations and confirmed the UK's wish for there to be a transition period to allow for a smooth withdrawal. The update, published on 16 January 2018, also sets out the MHRA's expectations for continued involvement in EU affairs during the negotiation period, while the UK remains part of the EU, and clarifies the MHRA's intended approach should a transition or implementation period not be concluded with the EU by March 2019.
Industries: Life Sciences and Healthcare
Jurisdictions: United Kingdom